NASDAQ:GRCE Grace Therapeutics Q1 2026 Earnings Report $2.15 -0.05 (-2.27%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Grace Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.22Beat/MissBeat by +$0.01One Year Ago EPSN/AGrace Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGrace Therapeutics Announcement DetailsQuarterQ1 2026Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time4:00PM ETUpcoming EarningsGrace Therapeutics' Q2 2027 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Grace Therapeutics Earnings HeadlinesGrace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateAugust 13, 2026 | finanznachrichten.deGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateAugust 13, 2026 | globenewswire.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.August 26 at 1:00 AM | Porter & Company (Ad)Grace Therapeutics, Stock Price HistoryAugust 4, 2026 | investing.comGrace Therapeutics Announces $10 Million Private PlacementAugust 4, 2026 | globenewswire.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationJuly 29, 2026 | finanznachrichten.deSee More Grace Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email. Email Address About Grace TherapeuticsGrace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.View Grace Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaisePhotronics Is Quietly Becoming a Key Winner From the AI BoomOpenAI’s Jalapeño Chip Could Change the AI Hardware RaceHONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger Prize Upcoming Earnings Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
